FILMARRAY® PNEUMONIA PANEL PLUS
Report
- Report Number
- 3002773840-2025-00018
- Event Type
- Death
- Date Received
- March 27, 2025
- Date of Event
- February 24, 2025
- Report Date
- April 18, 2025
- Manufacturer
- BIOFIRE DIAGNOSTICS, LLC
- Product Code
- QDS
- UDI-DI
- 00815381020314
- PMA / PMN Number
- K222601
- Adverse Event
- Yes
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- FR
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
- Health Professional
- Yes
Narratives
INVESTIGATION: THE PATIENT WAS A 65-YEAR-OLD MALE. THE CUSTOMER REPORTED THAT THE PATIENT WAS ADMITTED TO THE HOSPITAL ON (B)(6) 2025, WITH DYSPNEA AND HEMOPTYSIS. AT THE TIME OF TESTING, THE PATIENT WAS INTUBATED AND VENTILATED IN THE ICU AND ON TAZOBACTAM. ON (B)(6) 2025, A PATIENT'S BAL SAMPLE WAS TESTED ON FILMARRAY PNEUMONIA PANEL PLUS. THE FILMARRAY PNEUMONIA PANEL PLUS REPORTED ALL ANALYTES AS NOT DETECTED. ON (B)(6) 2025, THE PATIENT'S SAMPLE WAS RETESTED ON THE FILMARRAY PNEUMONIA PANEL PLUS. THE FILMARRAY PNEUMONIA PANEL PLUS REPORTED K. OXYTOCA, K. PNEUMONIAE GROUP, AND CTX-M AS DETECTED. THE CUSTOMER REPORTED CHEST COMPUTED TOMOGRAPHY (CT) SCAN WAS SUGGESTIVE OF CYTOMEGALOVIRUS INFECTION, CLINICAL WORSENING AND WORSENING OF LESIONS. ON AN UNKNOWN DATE, MEROPENEM FOR K.PNEUMONIAE ESBL WAS INTRODUCED. THE CUSTOMER STATED THAT THE PATIENT RAPIDLY IMPROVED ON (B)(6) 2025, WITH EXTUBATION. THE PATIENT DIED ON (B)(6) 2025. BIOFIRE'S INVESTIGATION INTO THIS EVENT IS ONGOING AND FURTHER INFORMATION HAS BEEN REQUESTED FROM THE CUSTOMER. THE FULL INVESTIGATION AND ASSOCIATED CONCLUSIONS WILL BE PROVIDED IN THE FINAL REPORT. CONCLUSION: INVESTIGATION ONGOING.
INVESTIGATION: THE PATIENT WAS A 65-YEAR-OLD MALE. THE CUSTOMER REPORTED THAT THE PATIENT WAS ADMITTED TO THE HOSPITAL ON (B)(6) 2025, WITH DYSPNEA AND HEMOPTYSIS. AT THE TIME OF TESTING, THE PATIENT WAS INTUBATED AND VENTILATED IN THE INTENSIVE CARE UNIT (ICU) AND ON TAZOBACTAM. ON (B)(6) 2025, A PATIENT'S BAL SAMPLE WAS TESTED ON FILMARRAY PNEUMONIA PANEL PLUS. NO RESULTS WERE OBTAINED DUE TO A CONTROL FAILURE. THE FILMARRAY PNEUMONIA PANEL PLUS WAS REPEATED 2 HOURS LATER. THE FILMARRAY PNEUMONIA PANEL PLUS REPORTED ALL ANALYTES AS NOT DETECTED. ON (B)(6) 2025, THE PATIENT'S SAMPLE WAS RETESTED ON THE FILMARRAY PNEUMONIA PANEL PLUS. THE FILMARRAY PNEUMONIA PANEL PLUS REPORTED K. OXYTOCA, K. PNEUMONIAE GROUP, AND CTX-M AS DETECTED. THE CUSTOMER REPORTED THAT THE NEGATIVE FILMARRAY PNEUMONIA PANEL PLUS RESULTS WERE COMMUNICATED TO THE PHYSICIAN IN THE EVENING OF (B)(6) 2025, AND THE MODIFIED RESULT WAS PROVIDED IN THE EARLY AFTERNOON OF (B)(6) 2025. THE SAME SAMPLE WAS USED FOR ADDITIONAL TESTING. AN UNKNOWN PCR TEST WAS POSITIVE FOR EPSTEIN-BARR VIRUS AND CYTOMEGALOVIRUS (CMV). THE CUSTOMER REPORTED THAT QUANTITATIVE CULTURE IDENTIFIED 3×10² K. PNEUMONIAE ESBL AND 10² STENOTROPHOMONAS MALTOPHILIA. NOTE, THE FILMARRAY PNEUMONIA PANEL PLUS DOES NOT DETECT S. MALTOPHILIA. THE PATIENT'S BLOOD SAMPLE WAS ALSO TESTED USING AN UNKNOWN PCR TEST AND WAS POSITIVE FOR CMV. WHEN ASKED IF THE PATIENT WAS AFFECTED BY THE FILMARRAY PNEUMONIA PANEL PLUS RESULT, THE CUSTOMER COMMUNICATED THE FOLLOWING: THE PATIENT WAS ADMITTED TO THE HOSPITAL ON (B)(6) 2025, WITH DYSPNEA AND HEMOPTYSIS, CHEST COMPUTED TOMOGRAPHY (CT) SCAN WAS SUGGESTIVE OF CYTOMEGALOVIRUS INFECTION, CLINICAL WORSENING AND WORSENING OF LESIONS ON CT SCAN, MEROPENEM FOR K.PNEUMONIAE ESBL WAS INTRODUCED, RAPID IMPROVEMENT WAS SEEN ON (B)(6) 2025, WITH EXTUBATION, AND THE PATIENT DIED ON (B)(6) 2025. IT IS UNKNOWN IF THE PATIENT WAS IMPACTED BY THE FILMARRAY PNEUMONIAE PANEL PLUS RESULT. BIOFIRE REQUESTED CLARIFICATION FROM THE CUSTOMER ON WHETHER THE PATIENT WAS AFFECTED BY THE FILMARRAY PNEUMONIAE PANEL PLUS RESULT, BUT DESPITE MULTIPLE ATTEMPTS, NO FURTHER INFORMATION WAS PROVIDED. CONCLUSION: BASED ON THE INFORMATION PROVIDED, THE INVESTIGATION FOUND THE MOST LIKELY CAUSE OF THE CONTROL FAILURE AND FALSE NEGATIVE K. OXYTOCA, K. PNEUMONIAE, AND CTX-M RESULTS WAS A REAGENT MANUFACTURING ERROR. PRELIMINARY INVESTIGATION INTO KIT LOT # 0979424/ POUCH LOT # 3BLF24 OF THE FILMARRAY PNEUMONIA PANEL PLUS IDENTIFIED INCREASED RISK OF CONTROL FAILURES AND FALSE NEGATIVE TEST RESULTS ON THIS SPECIFIC POUCH LOT. THIS WAS COMMUNICATED TO CUSTOMERS VIA FIELD SAFETY CORRECTIVE ACTION (FSCA) FA-TWD-000033, WHICH WAS ISSUED TO SUBSIDIARIES AND DISTRIBUTORS ON FEBRUARY 28, 2025. BIOFIRE IS CURRENTLY INVESTIGATING THE ISSUE AND TAKING APPROPRIATE CORRECTIVE AND PREVENTIVE ACTIONS. BIOFIRE RECOMMENDS THAT THE CUSTOMER FOLLOW THE INSTRUCTIONS IN FSCA FA-TWD-000033, INCLUDING STOPPING USE AND DISCARDING PRODUCT FROM KIT LOT # 0979424/ POUCH LOT # 3BLF24. CLINICAL PERFORMANCES CAN BE FOUND IN TABLES 22, 24, 56, AND 59 OF THE FILMARRAY PNEUMONIA PANEL PLUS IFU (WWW.ONLINE-IFU.COM/ITI0038).
SUMMARY: (B)(6) FRANCE, REPORTED A POTENTIAL FALSE NEGATIVE KLEBSIELLA OXYTOCA, KLEBSIELLA PNEUMONIAE GROUP, AND CTX-M RESULT ON THE FILMARRAY PNEUMONIA PANEL PLUS AFTER TESTING A PATIENT'S BRONCHOALVEOLAR LAVAGE (BAL) SAMPLE. IT IS UNKNOWN IF THERE WAS ANY IMPACT TO THE PATIENT DUE TO THE FILMARRAY PNEUMONIA PANEL PLUS RESULT. BIOFIRE HAS REQUESTED FURTHER INFORMATION FROM THE CUSTOMER AND IS CURRENTLY INVESTIGATING THIS EVENT.
SUMMARY: (B)(6) HÔPITAL (FRANCE) REPORTED A CONTROL FAILURE AND A POTENTIAL FALSE NEGATIVE KLEBSIELLA OXYTOCA, KLEBSIELLA PNEUMONIAE GROUP, AND CTX-M RESULT ON THE FILMARRAY PNEUMONIA PANEL PLUS AFTER TESTING A PATIENT'S BRONCHOALVEOLAR LAVAGE (BAL) SAMPLE. IT IS UNKNOWN IF THE PATIENT WAS IMPACTED DUE TO THE FILMARRAY PNEUMONIA PANEL PLUS RESULT. BASED ON THE INFORMATION PROVIDED, THE INVESTIGATION FOUND THAT THE MOST LIKELY CAUSE OF THE CONTROL FAILURE AND THE FALSE NEGATIVE K. OXYTOCA, K. PNEUMONIAE, AND CTX-M RESULTS WAS A REAGENT MANUFACTURING ERROR.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 2432621 | FILMARRAY® PNEUMONIA PANEL PLUS | FILMARRAY® PNEUMONIA PANEL PLUS | QDS | BIOFIRE DIAGNOSTICS, LLC | RFIT-ASY-0143 | 0979424 | 00815381020314 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 65 YR | Male | Death |